Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Change in Account Payables (2016 - 2025)

Apyx Medical's Change in Account Payables history spans 15 years, with the latest figure at -$155000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 120.5% year-over-year to -$155000.0; the TTM value through Dec 2025 reached $355000.0, up 663.49%, while the annual FY2025 figure was $355000.0, 663.49% up from the prior year.
  • Change in Account Payables reached -$155000.0 in Q4 2025 per APYX's latest filing, down from $328000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $782000.0 in Q1 2021 to a low of -$776000.0 in Q1 2023.
  • Average Change in Account Payables over 5 years is $76900.0, with a median of $169000.0 recorded in 2022.
  • The largest YoY upside for Change in Account Payables was 792.86% in 2023 against a maximum downside of 1421.57% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$401000.0 in 2021, then soared by 226.18% to $506000.0 in 2022, then increased by 26.09% to $638000.0 in 2023, then increased by 18.5% to $756000.0 in 2024, then tumbled by 120.5% to -$155000.0 in 2025.
  • Per Business Quant, the three most recent readings for APYX's Change in Account Payables are -$155000.0 (Q4 2025), $328000.0 (Q3 2025), and $513000.0 (Q2 2025).